BDI Pharma, Inc. (Formerly known as Blood Diagnostics, Inc.) to Provide Lundbeck Inc. (formerly Ovation Pharmaceuticals)'s ATryn -- the First Recombinant Antithrombin Approved in the U.S.

COLUMBIA, SC--(Marketwire - May 06, 2009) -

BDI Pharma, Inc. (BDI) announced today that it is the first specialty biopharmaceutical distributor to be recognized as an official authorized distributor for ATryn® (Antithrombin [Recombinant]). “We recognize the channel for this unique product’s distribution is to be limited and are very pleased to be the initial distributor of ATryn in the U.S.,” said William Shirey, Executive Vice President of BDI. “We, at BDI, embrace the partnership with Lundbeck and welcome the opportunity to introduce a recombinant antithrombin to our nation’s healthcare community.”

ATryn is approved by the U.S. Food and Drug Administration (FDA) for the prevention of perioperative and peripartum thromboembolic events in patients with hereditary antithrombin deficiency.

About ATryn

-- In 2006, ATryn was approved in the European Union through the centralized procedure. -- ATryn was developed to provide a safe, efficacious and consistent recombinant antithrombin that is readily available. Recombinant antithrombin has the same amino acid sequence as antithrombin derived from human plasma. The glycosylation profile of recombinant antithrombin is different from plasma derived antithrombin, which results in an increased heparin affinity. When assayed in the presence of excess of heparin the potency of the recombinant product is not different from that of plasma derived product. -- ATryn does not carry the risk of transmission of human blood borne diseases. Additionally, antithrombin concentrate from human plasma experienced supply shortages in the past while ATryn’s unique manufacturing process enables a safe and consistent supply of recombinant human antithrombin. 

About BDI Pharma, Inc.

Serving the healthcare community since 1995, BDI Pharma, Inc., the preeminent national wholesaler of specialty biopharmaceutical products, has built an outstanding reputation as an industry source for products and service. BDI Pharma’s market focus is evident in its commitment to specialty biotherapeutics, chemotherapies, immunologics and hemostatics, including Albumin (Human) USP, intravenous immune globulin (IVIG or IGIV), coagulation factors VIII, IX, and VIIa, as well as hyper-immunes, injectables and physician specialty pharmaceuticals. As a recognized Authorized Distributor of Record for the products it supplies nationwide, BDI Pharma services the entire country and is fully accredited and insured, fulfilling the licensing requirements in all 50 states.

In an arena where access to pertinent clinical data and updated information on market availability is paramount to patient care, BDI Pharma defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory management programs, unparalleled customer service, extensive product knowledge, unique promotional services, emergency availability and urgent need delivery. The company serves as a source for reference material and market data, offering healthcare providers the latest information on products, supply and other industry events. BDI Pharma’s educational literature and Web site -- www.bdipharma.com -- serve as open-access resources, contributing to the promotion of the biopharmaceutical industry and the education of both the healthcare community and general populace.